{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.5","upperLimit":"20.6","value":"18.3"},{"groupId":"OG001","lowerLimit":"9.9","upperLimit":"16.1","value":"13.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"134"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Velcade (Bortezomib)\n\nThalidomide\n\nDexamethasone\n\nMedian time to progression (primary end point): 19.5 months","id":"OG000","title":"Thal + Dex + Velcade"},{"description":"Standard treatment\n\nThalidomide\n\nDexamethasone\n\nMedian time to progression (primary end point): 13.8 months","id":"OG001","title":"Thal + Dex"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"3 year","title":"Progression Free Survival","type":"SECONDARY","unitOfMeasure":"months"}